Clinical Therapeutics and the Recognition of Drug-Induced Disease

References:

1. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occuring in association with terfenadine use. JAMA 1990;264:2788-2790.

2. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518.

3. Davies AJ, Harindra V, Mcewan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose (letter). Br Med J 1989;298:325.

4. Beard K. Adverse reactions as a cause of hospital admissions in the aged. Drugs Aging 1992;2:356-367.

5. D'Arcy PF. Epidemiological aspects of iatrogenic disease. In: D'Arcy PF, Griffin JP, editors. Iatrogenic diseases. Oxford: Oxford University Press, 1986:29-58.

6. Nolan L, O'Malley K. Prescribing for the elderly. Part I: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988;36:142-149.

7. Koch KE. Adverse drug reactions. In: Brown T, editor. Handbook of institutional pharmacy practice. 3rd ed. Bethesda, MD: American Society of Hospital Pharmacists, 1992:279-291.

8. Lakshmanan MC, Hershey CO, Breslau B. Hospital admissions caused by iatrogenic disease. Arch Intern Med 1986;146:1931-1934.

9. Burnum JF. Preventability of adverse dug reactions (letter). Ann Intern Med 1976;85:80-81.

10. Kessler DA. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269:2765-2768.

11. Alter, BP. Bone marrow failure disorders. Mt Sinai J Med 1991;58:521-534.

12. Wallace Laboratories. Express telegram to physicians. Cranbury, NJ: Wallace Laboratories, August 1, 1994.

13. Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981;2:93-94.

14. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. 4th ed. Oxford: Oxford University Press, 1991:18-45.

15. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992;34:377-395.

16. Zimmerman HJ. Hepatoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Centruy-Crofts, 1978.

17. Vincent PC. Drug-induced aplastic anemia and agranulocytosis: incidence and mechanisms. Drugs 1986;31:52-63.

18. Chan H-L, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM. The incidence of erythema multiforme Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-47.

19. Stephens MDB. Has the patient suffered an ADR? - assessment of drug causality. In: International Drug Surveillance Department, Glaxo Group Research Ltd. Drug safety: a shared responsibility. London: Churchill Livingstone, 1991;47-56.

20. Green DM. Pre-existing conditions, placebo reactions, and "side effects". Ann Intern Med 1964;60:255-265.

21. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968;279:678-679.

22. Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. Adverse drug reactions - a matter of opinion. ClinPharmacol Ther 1976;19:489-492.

23. Irey NS. Tissue reactions to drugs. Am J Pathol 1976;82:617-647.

24. Johnson JM, Barash D. A review of postmarketing adverse drug experience reporting requirements. Food Drug Cosmetic Law J 1991;46:665-672.

25. Joint Commission on Accreditation of Healthcare Organizations. Accreditation manual for hospitals, 1994. Oakbrook Terrace, IL: The Commission, 1993.

26. DeGowin RL. The medical hostory. In: DeGowin RL, editor. Bedside diagnostic examination. 5th ed. New York: Macmillan Publishing Company, 1987:14-35.

Return to the Table of Contents